Compare AXGN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | ARQT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2013 | 2020 |
| Metric | AXGN | ARQT |
|---|---|---|
| Price | $42.83 | $21.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $42.33 | $34.00 |
| AVG Volume (30 Days) | 687.9K | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | $225,208,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $20.57 | $34.85 |
| Revenue Next Year | $16.68 | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 20.21 | ★ 91.34 |
| 52 Week Low | $9.22 | $12.72 |
| 52 Week High | $45.83 | $31.77 |
| Indicator | AXGN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 48.26 |
| Support Level | $29.48 | $21.12 |
| Resistance Level | $44.83 | $21.95 |
| Average True Range (ATR) | 1.84 | 0.83 |
| MACD | -0.09 | 0.17 |
| Stochastic Oscillator | 74.86 | 73.40 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.